Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
AstraZeneca
Mallinckrodt
Dow
Merck

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR ENTRESTO


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Entresto

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02636283 ↗ Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease Terminated American Heart Association Phase 2 2017-12-31 This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
NCT02636283 ↗ Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease Terminated University of Minnesota Phase 2 2017-12-31 This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
NCT02636283 ↗ Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease Terminated University of Minnesota - Clinical and Translational Science Institute Phase 2 2017-12-31 This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
NCT02682719 ↗ Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation Active, not recruiting Novartis Ireland Ltd Phase 2 2015-12-16 Sacubitril-valsartan, an Angiotensin Receptor Blocker-Neprilysin Inhibitor (ARNI), currently marketed for the management of heart failure, has been shown to reduce cardiovascular morbidity and mortality in stage C heart failure with reduced ejection fraction. In stage C HFpEF, sacubitril-valsartan has also been shown to reduce left atrial volume index measured using echocardiography over a 9 month timeframe. The PARABLE study investigates the hypothesis that sacubitril-valsartan can provide benefits in terms of left atrial structure and function as well as left ventricular structure and function in asymptomatic (stage A/B HFpEF) patients. This is a prospective, randomised, double-blind, double-dummy, phase II study design. The patient population will have hypertension and/or diabetes together with preserved ejection fraction, elevated natriuretic peptide (NP) and abnormal left atrial volume index (LAVI, > 28 mL/m2).
NCT02682719 ↗ Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation Active, not recruiting The Heartbeat Trust Phase 2 2015-12-16 Sacubitril-valsartan, an Angiotensin Receptor Blocker-Neprilysin Inhibitor (ARNI), currently marketed for the management of heart failure, has been shown to reduce cardiovascular morbidity and mortality in stage C heart failure with reduced ejection fraction. In stage C HFpEF, sacubitril-valsartan has also been shown to reduce left atrial volume index measured using echocardiography over a 9 month timeframe. The PARABLE study investigates the hypothesis that sacubitril-valsartan can provide benefits in terms of left atrial structure and function as well as left ventricular structure and function in asymptomatic (stage A/B HFpEF) patients. This is a prospective, randomised, double-blind, double-dummy, phase II study design. The patient population will have hypertension and/or diabetes together with preserved ejection fraction, elevated natriuretic peptide (NP) and abnormal left atrial volume index (LAVI, > 28 mL/m2).
NCT02682719 ↗ Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation Active, not recruiting Mark Ledwidge Phase 2 2015-12-16 Sacubitril-valsartan, an Angiotensin Receptor Blocker-Neprilysin Inhibitor (ARNI), currently marketed for the management of heart failure, has been shown to reduce cardiovascular morbidity and mortality in stage C heart failure with reduced ejection fraction. In stage C HFpEF, sacubitril-valsartan has also been shown to reduce left atrial volume index measured using echocardiography over a 9 month timeframe. The PARABLE study investigates the hypothesis that sacubitril-valsartan can provide benefits in terms of left atrial structure and function as well as left ventricular structure and function in asymptomatic (stage A/B HFpEF) patients. This is a prospective, randomised, double-blind, double-dummy, phase II study design. The patient population will have hypertension and/or diabetes together with preserved ejection fraction, elevated natriuretic peptide (NP) and abnormal left atrial volume index (LAVI, > 28 mL/m2).
NCT02754518 ↗ Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis Completed University of Chicago Phase 4 2016-04-01 This study intends to measure the effects of valsartan/sacubitril compared to baseline standard medical heart failure therapy on reverse remodeling using echocardiographic endocardial surface analysis techniques to assess changes in ventricular volume, function, and shape.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Entresto

Condition Name

Condition Name for Entresto
Intervention Trials
Heart Failure 13
Hypertension 5
Heart Failure With Preserved Ejection Fraction 3
Diastolic Dysfunction 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Entresto
Intervention Trials
Heart Failure 23
Hypertension 4
Ventricular Remodeling 3
Diabetes Mellitus, Type 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Entresto

Trials by Country

Trials by Country for Entresto
Location Trials
United States 36
Canada 9
Ireland 5
France 3
Denmark 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Entresto
Location Trials
Minnesota 5
Tennessee 4
Massachusetts 3
Ohio 3
Illinois 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Entresto

Clinical Trial Phase

Clinical Trial Phase for Entresto
Clinical Trial Phase Trials
Phase 4 18
Phase 3 2
Phase 2 10
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Entresto
Clinical Trial Phase Trials
Recruiting 13
Completed 9
Not yet recruiting 4
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Entresto

Sponsor Name

Sponsor Name for Entresto
Sponsor Trials
Novartis Pharmaceuticals 4
Vanderbilt University Medical Center 3
The Heartbeat Trust 3
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Entresto
Sponsor Trials
Other 63
Industry 10
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Merck
McKesson
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.